Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma

This article was originally published in PharmAsia News

Executive Summary

SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
Advertisement

Related Content

Pfizer's Viagra Challenged As Korea's JW Choongwae Launches ED Product In Korea
Korean Pharma Earnings Roundup: Dong-A, Green Cross Retain Leading Positions While Yuhan, LG Life, Hanmi Struggle
Korea's Ildong Pharmaceutical In Licensing Deal With Taiwan Liposome Firm To Sell Product In Korean Market
Korea's Dong-A Regains Top Spot From Green Cross In Q2 Sales
GSK Korea Head Rebuffs Speculation About Hostile Takeover Of Dong-A
South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment
Korea's Hanmi And Merck Move To Sell Hanmi's Hypertension Drug In North America, China and Europe
Korea's Hanmi And Merck in Discussion to Sell Hanmi's Hypertension Drug In Other Countries including Six Asia-Pacific Countries
Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena
GlaxoSmithKline's Witty Plays Down Impact Of U.S. Health Care Reform
Advertisement
UsernamePublicRestriction

Register

SC074781

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel